Skip to content
Saturday, May 23, 2026
Latest:
  • Your hemorrhoid playbook: The AGA’s first expert review
  • A promising new strategy for treating dry eye disease
  • Congratulations to the Baylor College of Medicine class of 2026!
  • The psychological impacts of Hurricane Helene
  • Baylor recognizes research excellence with DeBakey Awards
Baylor College of Medicine Blog Network

  • Home
  • Momentum
    • About Momentum
    • Resources
    • Contributors
      • Taylor Barnes
      • Dana Benson
      • Molly Chiu
      • Julie Garcia
      • Graciela Gutierrez
      • Anna Kiappes
      • Aries Payne
      • Andy Phifer
      • Homa Warren
      • Melissa Tucker
    • Contact Us
  • From The Labs
    • About From the Labs
    • Follow From The Labs on Twitter
  • Policywise
    • About PolicyWise
    • Follow @BCMEthics on Twitter
  • The Stitch
    • About The Stitch
  • Progress Notes
    • About Progress Notes
    • Progress Notes Editors
    • Connect With Us
  • bcm.edu

ACTL6A

From The Labs

A new mechanism of cisplatin resistance in cancer, and how to reverse it

April 22, 2021 ACTL6A,  cancer resistance to therapy,  cisplatin,  DNA repair,  epigenetic chromatin remodeling,  panobinostat,  Research

ACLT6A overexpression confers cancer cells resistance to cisplatin, and researchers found a way to reverse it.

Read More

From the Labs: Image of the Month

Cell cluster of triple-negative breast cancer. Courtesy of the C. Cheng lab From the Labs: Breast cancer cell clusters

Healthy Habits: A DOC-umentary Series

https://www.youtube.com/watch?v=SlNiMWHUhbc

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951